The history of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial release generated substantial returns, the end of its intellectual property protection opened the avenue to https://ezmarkbookmarks.com/story21765982/the-copyright-and-big-pharma-a-risky-bet